255 related articles for article (PubMed ID: 16549331)
1. Chemotherapy for advanced pancreatic cancer.
Chua YJ; Cunningham D
Best Pract Res Clin Gastroenterol; 2006 Apr; 20(2):327-48. PubMed ID: 16549331
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.
Heinemann V
Semin Oncol; 2002 Dec; 29(6 Suppl 20):9-16. PubMed ID: 12577228
[TBL] [Abstract][Full Text] [Related]
3. New perspectives in the management of pancreas cancer.
Haller DG
Semin Oncol; 2003 Aug; 30(4 Suppl 11):3-10. PubMed ID: 14506598
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel in the management of advanced pancreatic cancer.
Lopes G; Rocha Lima CM
Semin Oncol; 2005 Apr; 32(2 Suppl 4):S10-23. PubMed ID: 16015551
[TBL] [Abstract][Full Text] [Related]
5. Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.
Vogel A; Ciardiello F; Hubner RA; Blanc JF; Carrato A; Yang Y; Patel DA; Ektare V; de Jong FA; Gill S
Cancer Treat Rev; 2016 Nov; 50():142-147. PubMed ID: 27676174
[TBL] [Abstract][Full Text] [Related]
6. Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer.
Oh SY; Kim HJ; Kim TH; Lee GW; Kim HG; Jeong CY; Kwon HC; Kang JH
Invest New Drugs; 2010 Jun; 28(3):343-9. PubMed ID: 19444385
[TBL] [Abstract][Full Text] [Related]
7. Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Li J; Saif MW
JOP; 2009 Jul; 10(4):361-5. PubMed ID: 19581735
[TBL] [Abstract][Full Text] [Related]
8. Advanced pancreatic cancer: is there a role for combination therapy?
Kulke MH
Expert Rev Anticancer Ther; 2003 Oct; 3(5):729-39. PubMed ID: 14599095
[TBL] [Abstract][Full Text] [Related]
9. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
Ellenrieder V; König A; Seufferlein T
Digestion; 2016; 94(1):44-9. PubMed ID: 27438590
[TBL] [Abstract][Full Text] [Related]
10. [Second line chemotherapy for pancreatic cancer].
Park JY
Korean J Gastroenterol; 2011 Apr; 57(4):207-12. PubMed ID: 21519173
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapeutic agents eligible for prior dosing in pancreatic cancer patients requiring hemodialysis: a systematic review
.
Hann A; Nosalski E; Hermann PC; Egger J; Seufferlein T; Keller F
Clin Nephrol; 2018 Aug; 90(2):125-141. PubMed ID: 29578402
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma.
Kozuch P; Petryk M; Bruckner HW
Hematol Oncol Clin North Am; 2002 Feb; 16(1):123-38. PubMed ID: 12063823
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of different chemotherapy regimens in treatment of advanced or metastatic pancreatic cancer: A network meta-analysis.
Zhang SH; Liu GF; Li XF; Liu L; Yu SN
J Cell Physiol; 2018 Apr; 233(4):3352-3374. PubMed ID: 28926090
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy for advanced pancreatic cancer.
Haller DG
Int J Radiat Oncol Biol Phys; 2003; 56(4 Suppl):16-23. PubMed ID: 12826247
[TBL] [Abstract][Full Text] [Related]
15. A predictive model for evaluating responsiveness to pemetrexed treatment in patients with advanced colorectal cancer.
Wu XY; Huang XE; Cao J; Shi L; Xu X; Qian ZY
Asian Pac J Cancer Prev; 2014; 15(14):5941-4. PubMed ID: 25081726
[TBL] [Abstract][Full Text] [Related]
16. [Gemcitabine-based combinations in inoperable pancreatic cancers].
Louvet C; André T; Artru P
Bull Cancer; 2002 Aug; 89 Spec No():S96-101. PubMed ID: 12449038
[TBL] [Abstract][Full Text] [Related]
17. Conventional chemotherapy of advanced pancreatic cancer.
Giuliani F; Di Maio M; Colucci G; Perrone F
Curr Drug Targets; 2012 Jun; 13(6):795-801. PubMed ID: 22458526
[TBL] [Abstract][Full Text] [Related]
18. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.
Yoo C; Hwang JY; Kim JE; Kim TW; Lee JS; Park DH; Lee SS; Seo DW; Lee SK; Kim MH; Han DJ; Kim SC; Lee JL
Br J Cancer; 2009 Nov; 101(10):1658-63. PubMed ID: 19826418
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens.
Wainberg ZA; Feeney K; Lee MA; Muñoz A; Gracián AC; Lonardi S; Ryoo BY; Hung A; Lin Y; Bendell J; Hecht JR
BMC Cancer; 2020 Jul; 20(1):633. PubMed ID: 32641104
[TBL] [Abstract][Full Text] [Related]
20. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.
Lee MG; Lee SH; Lee SJ; Lee YS; Hwang JH; Ryu JK; Kim YT; Kim DU; Woo SM
Chemotherapy; 2013; 59(4):273-9. PubMed ID: 24457620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
